Company Filing History:
2 out of 3 
1 out of 13 
1 out of 1 Years Active: 2014-2016
Title: **Christopher R G Jones: Innovator in Chemosensory Receptor Ligand-Based Therapies**
Introduction
Christopher R G Jones, based in San Diego, California, is an accomplished inventor with a focus on innovative solutions in the realm of metabolic diseases. With a total of four patents to his name, Jones has significantly contributed to the field of biomedical research with his pioneering work on chemosensory receptor ligands.
Latest Patents
Among his recent patents, Jones has developed methodologies for treating diabetes, obesity, and other metabolic conditions utilizing chemosensory receptor ligands. His innovative approaches include the preparation of formulations that target these receptors, aiming to optimize therapeutic outcomes. Additionally, he holds patents that detail methods for modulating hormone concentrations through the administration of compositions containing these ligands, specifically designed to deliver them to targeted regions of the intestine. This work encompasses the modulation of various hormones critical to metabolic regulation, including GLP-1, insulin, and ghrelin, thereby highlighting his impact on metabolic health.
Career Highlights
Jones has made notable strides in his career by working with reputable companies such as Ambra Bioscience and Elcelyx Therapeutics. His tenure at these organizations has solidified his expertise in developing cutting-edge therapies that address significant health challenges related to metabolism.
Collaborations
During his career, Jones has collaborated with recognized professionals in the field, including Alain D Baron and Martin R Brown. These partnerships have contributed to his advancement and innovation in chemosensory receptor research, fostering a teamwork dynamic that promotes creative solutions in therapeutic applications.
Conclusion
Christopher R G Jones stands out as a key figure in the realm of metabolic disease research, with his inventive spirit driving the development of novel therapies. His ongoing commitment to understanding and tackling complex metabolic disorders through chemosensory receptor ligands positions him as a leading inventor in the health sciences sector.